X4 Pharmaceuticals Stock Analysis

XFOR Stock Analysis Notes

About 54.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.39. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. X4 Pharmaceuticals recorded a loss per share of 5.7. The entity last dividend was issued on the 27th of June 2021. The firm had 1:30 split on the 27th of December 2021. X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. The company was founded in 2010 and is headquartered in Boston, Massachusetts. X4 Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 83 people. For more information please call Paula Ragan at 857 529 8300 or visit https://www.x4pharma.com.

X4 Pharmaceuticals Investment Alerts

X4 Pharmaceuticals Upcoming and Recent Events

XFOR Largest EPS Surprises

View All Earnings Estimates

X4 Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

XFOR Stock Institutional Investors

Note, although X4 Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

XFOR Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 25.18 M.

XFOR Profitablity

Management Efficiency

X4 Pharmaceuticals has return on total asset (ROA) of (0.6018) % which means that it has lost $0.6018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0226) %, meaning that it created substantial loss on money invested by shareholders. X4 Pharmaceuticals' management efficiency ratios could be used to measure how well X4 Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/30/2025, Return On Tangible Assets is likely to drop to -0.33. In addition to that, Return On Capital Employed is likely to drop to -0.34. As of 04/30/2025, Net Tangible Assets is likely to grow to about 68.5 M, while Total Assets are likely to drop slightly above 108.3 M.

Technical Drivers

As of the 30th of April, X4 Pharmaceuticals owns the information ratio of (0.15), and Market Risk Adjusted Performance of (8.80). In connection with fundamental indicators, the technical analysis model lets you check timely technical drivers of X4 Pharmaceuticals, as well as the relationship between them. Please check out X4 Pharmaceuticals market risk adjusted performance and treynor ratio to decide if X4 Pharmaceuticals is priced more or less accurately, providing market reflects its prevailing price of 4.31 per share. Given that X4 Pharmaceuticals has information ratio of (0.15), we strongly advise you to confirm X4 Pharmaceuticals's latest market performance to make sure the company can sustain itself sooner or later.

X4 Pharmaceuticals Price Movement Analysis

X4 Pharmaceuticals Insider Trading Activities

X4 Pharmaceuticals Outstanding Bonds

X4 Pharmaceuticals Predictive Daily Indicators

X4 Pharmaceuticals Corporate Filings

X4 Pharmaceuticals Forecast Models

X4 Pharmaceuticals' time-series forecasting models are one of many X4 Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary X4 Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how X4 Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling XFOR shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as X4 Pharmaceuticals. By using and applying XFOR Stock analysis, traders can create a robust methodology for identifying XFOR entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. XFOR analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. XFOR analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

X4 Pharmaceuticals stock analysis indicators help investors evaluate how X4 Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading X4 Pharmaceuticals shares will generate the highest return on investment. By understating and applying X4 Pharmaceuticals stock analysis, traders can identify X4 Pharmaceuticals position entry and exit signals to maximize returns.

When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.